ZCUBE-ZAMBON-RESEARCH
Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences. Starting this year, the program will focus on the femtech sector and will feature a new format. The initiative, one of the first internationally in terms of focus and invested capital, invites startups and entrepreneurial ideas aimed at developing products and services to address major medical needs and improve women's health and well-being. The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.
The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16. At the end of the selection process, up to 5 startups will be identified to receive an investment of €100,000 each, through a SAFE (Simple Agreement for Future Equity) agreement and will have access to a training and mentoring program delivered by experts in the fields of investments, business development, venture capital, intellectual property, regulatory affairs, and market access.
Startups with the highest potential will also have the opportunity to build a partnership with the Zambon group, accelerating their market access phase and commercial positioning on a global scale.
“We are eager to launch the fifth edition of Open Accelerator; we are excited to discover which companies can bring innovative solutions to change the Life Sciences and women’s health sector. The choice to dedicate the 2024 edition to the femtech sector is deliberate: working in unexplored areas can contribute to creating benefits for the global economy. As highlighted by recent studies, bridging this gender gap is essential” - said Giovanni Magnaghi, President of Zcube and Chief Financial Officer of Zambon – “Since 2016, Open Accelerator has allowed us to offer direct access to capital and expertise to new and promising entrepreneurial ideas, thanks to the collaboration with prominent partners participating in the open innovation ecosystem at our scientific campus, OpenZone, where part of the program is hosted”.
The previous four editions of the program selected 46 startups from 23 countries, 8 of which have received up to €100,000 each in seed investment. The winner of the Distinction Award during the last edition of Open Accelerator comes from the femtech sector: Hyivy Health, a Canadian startup developing a medical device for pelvic floor rehabilitation. Founded in 2019 by Canadian entrepreneur Rachel Bartholomew following a diagnosis of cervical cancer, Hyivy Health aims to improve the standard of care for both patients and physicians through a holistic approach. Bartholomew, CEO of Hyivy Health, commented on the launch of the new edition of Open Accelerator: “It is a turning point for the industry. Open Accelerator is one of the first programs to enter this field with resources and real opportunities for femtech startups on a global level”.
“Open Accelerator values the experience of Zcube and best expresses our vision of Zambon as an open company, where open innovation serves as a lever for cultural and entrepreneurial growth for both us and the entire system” - commented Elena Zambon, President of Zambon and creator of Open Accelerator – “Women's health is a fundamental focus for Zambon and a central issue in international health agendas: supporting these entities and helping them bringing their innovative entrepreneurial ideas to market is an additional effort by our group to innovate cure and care to make patients’ lives better”.
Coordinating Open Accelerator will be a team of professionals experienced in Life Sciences and Venture Capital including Federica Destro, External Innovation & Community manager at Zcube, Vittoria Pavoncello, Technology Scouting & Investment Specialist at Zcube, Michele Gaiotto, CEO of HTH and Advisor to Zcube, and Marco Gullà, Investment Associate at HTH.
For more information about the program, visit www.openaccelerator.it/
For more information about Zcube, visit www.zambon.com/en/innovation/zcube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226030549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom